Neurogenic Bladder Clinical Trial
— PReSuTINeBOfficial title:
Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study
Verified date | March 2020 |
Source | Buckinghamshire Healthcare NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Due to the damage caused to the spinal cord, patients with spinal cord injury, cauda equina syndrome, multiple sclerosis and transverse myelitis may encounter loss of bladder function, which in turn can lead to a debilitating and costly complication: Urinary Tract Infections (UTIs). Given that these patients with loss of bladder function do not normally feel symptoms like pain - as would be the case in otherwise healthy persons - there is no clear agreement among experts on which signs and symptoms are indicative of a UTI. Although strong evidence is lacking, antibiotics have been widely used for prevention of recurrent UTIs in patients with loss of bladder function. However, this approach is now being questioned as antibiotic resistance has become a world-wide health concern. Policy makers recently stressed the importance of research into alternative preventative treatments. The use of immunotherapy is one such an alternative approach, which works by stimulating the body's immune system. One of these immunotherapy is a Uro-Vaxom® oral capsule which consists of inactivated traces of the bacteria that normally cause at least 83% of UTIs in patients with loss of bladder function. Previous studies show that Uro-Vaxom® resulted in a significant reduction of UTIs in otherwise healthy patients, as well as being safe to use. Before investigating the effects of this promising new immunotherapy, this proposed study aims to clarify two crucial issues. First, after reviewing the literature and appraising patients', carers' and healthcare professionals' experiences, the aim is to reach an agreement on how to measure a symptomatic UTI in patients with loss of bladder function that results from a spinal cord lesion. Second, using Uro-Vaxom® Investigators aim to conduct a smallscale, placebo-controlled trial with 48 participants to investigate the feasibility of carrying out a larger trial on prevention of symptomatic UTI in such patients.
Status | Completed |
Enrollment | 48 |
Est. completion date | September 21, 2019 |
Est. primary completion date | August 2, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Have a clinical diagnosis of spinal cord injury, multiple sclerosis, transverse myelitis or cauda equina damage; - Have had the diagnosis of the spinal pathology for at least 12 months; - Have not had any significant changes in the underlying condition for 12 weeks - Be living in the community (not in residential care) - Aged 18 to 75 years - Have had at least three urinary tract infection episodes treated using anti-biotics over the preceding 12 months; - If a woman of child-bearing age, is willing to use contraception for the duration of the study - Having the mental capacity to give informed consent Exclusion Criteria: - Have had surgical alterations to the bladder, excluding supra-pubic catherisation. - Known hypersensitivity to the active principle or to any of the excipients of Uro-Vaxom® - Being unwilling to take a product containing gelatin (e.g. vegetarians) - recruitment can be postponed until antibiotics have not been used for a period of 14 days and symptoms of a UTI have subsided |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Stoke Mandeville Hospital | Aylesbury | Buckinghamshire |
United Kingdom | Oxford Centre for Enablement | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
Buckinghamshire Healthcare NHS Trust | National Institute for Health Research, United Kingdom, Oxford Clinical Trials Research Unit |
United Kingdom,
Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC; Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005 Apr;47(4):542-8; discussion 548. Epub 2005 Jan 21. — View Citation
Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys Ther. 2002 Jun;82(6):601-12. Review. — View Citation
Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012 Jun;11(6):663-76. doi: 10.1586/erv.12.36. Review. — View Citation
Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D'Elia C, Malossini G, Boddi V, Bartoletti R. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis. 2012 Sep;55(6):771-7. doi: 10.1093/cid/cis534. Epub 2012 Jun 7. — View Citation
Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P, Sipski M, Cohen R, Blight AR. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007 Feb;45(2):158-68. Epub 2006 Jun 13. — View Citation
D'Hondt F, Everaert K. Urinary tract infections in patients with spinal cord injuries. Curr Infect Dis Rep. 2011 Dec;13(6):544-51. doi: 10.1007/s11908-011-0208-6. — View Citation
Ersoz M, Tunc H, Akyuz M, Ozel S. Bladder storage and emptying disorder frequencies in hemorrhagic and ischemic stroke patients with bladder dysfunction. Cerebrovasc Dis. 2005;20(5):395-9. Epub 2005 Oct 3. — View Citation
Esclarín De Ruz A, García Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000 Oct;164(4):1285-9. — View Citation
Gupta A, Taly AB, Srivastava A, Murali T. Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord. 2009 Apr;47(4):307-11. doi: 10.1038/sc.2008.123. Epub 2008 Oct 21. — View Citation
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9. — View Citation
Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2013 Nov 18;(11):CD004375. doi: 10.1002/14651858.CD004375.pub4. Review. — View Citation
Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006 Jun;50(6):2251-4. — View Citation
Khatri B, Basnyat S, Karki A, Poudel A, Shrestha B. Etiology and antimicrobial susceptibility pattern of bacterial pathogens from urinary tract infection. Nepal Med Coll J. 2012 Jun;14(2):129-32. — View Citation
Lavy C, James A, Wilson-MacDonald J, Fairbank J. Cauda equina syndrome. BMJ. 2009 Mar 31;338:b936. doi: 10.1136/bmj.b936. Review. — View Citation
Magasi P, Pánovics J, Illés A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26(2):137-40. — View Citation
Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, Jones JK. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011 Mar;30(3):395-401. doi: 10.1002/nau.21003. Epub 2010 Sep 29. — View Citation
Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001 Oct 4;345(14):1007-13. — View Citation
Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9. Review. — View Citation
Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009 Feb;33(2):111-9. doi: 10.1016/j.ijantimicag.2008.08.011. Epub 2008 Oct 28. Review. — View Citation
NICE guidelines: Urinary incontinence in neurological disease: Management of lower urinary tract dysfunction in neurological disease. https://www.nice.org.uk/guidance/cg148/chapter/1-guidance
Plowman, R., Graves, N., Griffin, M., Swan, A., Cookson, B., Taylor, L. 1999. The socio-economic burden of healthcare associated infection. PHLS.
Richie, J. and Spencer, L. Qualitative data analysis for applied policy research. In Analysing Qualitative Data. (eds A.Bryman and R.Burgess). 1994:173-194. London: Routledge
Rubin SM. Management of multiple sclerosis: an overview. Dis Mon. 2013 Jul;59(7):253-60. doi: 10.1016/j.disamonth.2013.03.012. Review. — View Citation
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009 Nov;34(5):407-13. doi: 10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7. — View Citation
Schmidhammer S, Ramoner R, Höltl L, Bartsch G, Thurnher M, Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002 Sep;60(3):521-6. — View Citation
Schulman CC, Corbusier A, Michiels H, Taenzer HJ. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993 Sep;150(3):917-21. — View Citation
Sedor J, Mulholland SG. Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol Clin North Am. 1999 Nov;26(4):821-8. Review. — View Citation
Street JT, Noonan VK, Cheung A, Fisher CG, Dvorak MF. Incidence of acute care adverse events and long-term health-related quality of life in patients with TSCI. Spine J. 2015 May 1;15(5):923-32. doi: 10.1016/j.spinee.2013.06.051. Epub 2013 Aug 24. — View Citation
Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990 Jan;65(1):6-9. — View Citation
Werndle MC, Zoumprouli A, Sedgwick P, Papadopoulos MC. Variability in the treatment of acute spinal cord injury in the United Kingdom: results of a national survey. J Neurotrauma. 2012 Mar 20;29(5):880-8. doi: 10.1089/neu.2011.2038. Epub 2011 Oct 26. — View Citation
West TW. Transverse myelitis--a review of the presentation, diagnosis, and initial management. Discov Med. 2013 Oct;16(88):167-77. Review. — View Citation
Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011 Apr;9(4):233-43. doi: 10.1038/nrmicro2536. Epub 2011 Feb 28. Review. — View Citation
* Note: There are 32 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Checklist or consensus guideline which can be used to measure a symptomatic urinary tract infection and Practicality of carrying out a definitive randomised controlled clinical study | 23 months | ||
Secondary | Number of participants willing to participate | 14 months | ||
Secondary | Number of successfully collected urine samples via courier | 14 months | ||
Secondary | Drug compliance | Measured by the number of un-used drug packs that the participants will return upon each hospital visit | 14 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Enrolling by invitation |
NCT06429631 -
The Effect of CIC Education on QOL and Compliance With Mobile Application in Individuals With Spinal Cord Injury.
|
N/A | |
Completed |
NCT03573726 -
Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life
|
N/A | |
Recruiting |
NCT06059066 -
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
Completed |
NCT01429090 -
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
|
Phase 1 | |
Recruiting |
NCT05587101 -
Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
|
||
Terminated |
NCT03843073 -
Connected Catheter- Safety and Effectiveness Study
|
N/A | |
Terminated |
NCT04059159 -
Connected Catheter - Safety and Effectiveness Study
|
N/A | |
Completed |
NCT05861024 -
Urinary Calculi After Bladder Augmentation in Children
|
||
Completed |
NCT05858840 -
Urinary Artificial Sphincter in Children
|
||
Completed |
NCT04074616 -
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
|
N/A | |
Completed |
NCT05683938 -
GentleCath™ Air Intermittent Catheter Smartwatch Real Life Pilot Study
|
||
Completed |
NCT04543552 -
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
|
||
Active, not recruiting |
NCT06247033 -
Efficacies of Different Managements in Patients With Overactive Bladder With Stroke
|
N/A | |
Withdrawn |
NCT01305681 -
Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization
|
Phase 1/Phase 2 | |
Recruiting |
NCT04248322 -
Qualitative Assessment of the Impact of TTNS on QOL and Participation
|
||
Recruiting |
NCT05301335 -
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
|
N/A | |
Recruiting |
NCT04924569 -
Continence Care Registry
|
||
Completed |
NCT01716624 -
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
|
Phase 3 | |
Completed |
NCT01297647 -
Incidence of Urinary Tract Infection After Urodynamic Investigation
|
N/A |